Drugs / Regaine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03351322 Comparator | May 2018 → Nov 2019 | androgenetic alopecia | Energenesis Biomedical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Regaine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03351322 ↗ |
| Route | Topical | “Regaine, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks” NCT03351322 ↗ |